Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfizer C. difficile Vaccine 2-Dose vs 3-Dose Study
NCT03918629Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Clostridium difficile vaccine in Clostridioides difficile infection (CDI), sponsored by Pfizer. Started Apr 2019; status: completed.
02
Drugs
Clostridium difficile vaccine
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03918629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918629.